Thursday, Apr 30, 2026
English News
  • Hyderabad
  • Telangana
  • AP News
  • India
  • World
  • Entertainment
  • Sport
  • Science and Tech
  • Business
  • Rewind
  • ...
    • NRI
    • View Point
    • cartoon
    • My Space
    • Education Today
    • Reviews
    • Property
    • Lifestyle
E-Paper
  • NRI
  • View Point
  • cartoon
  • My Space
  • Reviews
  • Education Today
  • Property
  • Lifestyle
Home | Business | Cancer Clinics Raises Pre Series A Funding From Axilor Others

Cancer Clinics raises pre-Series A funding from Axilor, others

Hyderabad-headquartered comprehensive cancer care provider expects to close Series A funding in the second half of 2021

By Telangana Today
Published Date - 23 March 2021, 01:34 PM
Cancer Clinics raises pre-Series A funding from Axilor, others
whatsapp facebook twitter telegram

Hyderabad: Hyderabad-based Cancer Clinics, a unit of Cipher Oncology, closed pre-Series A funding of $1.5 million (about Rs 11 crore) led by Axilor Ventures. M- Venture Partners (MVP), a Singapore-based early-stage fund, also participated marking its debut in India.

Other investors who participated include Natco Pharma, Hyderabad-based pharma and infrastructure entrepreneurs, leaders of Bharti group, senior partners from McKinsey, and ISB alumni.


Cancer Clinics aims to improve access to and affordability of holistic oncology and completely reimagine how cancer is managed. The company launched its first two centres in Hyderabad in February 2020 and is now planning to add four more centres in the next few months and expand outside Hyderabad.

A substantial oncology practice is being scaled and Cancer Clinics expects to close Series A funding in the second half of 2021.

The company said, despite the disruption caused by the pandemic, it was able to establish product-market fit, attract an accomplished panel of oncologists and is getting encouraging traction from patients.

Within its first year of operation, Cancer Clinics has been able to implement evidence-based care pathways and demonstrate improved clinical outcomes while reducing the financial burden on patients.

Prachi Sinha, Healthcare Lead from Axilor said, “Currently, even the meagre infrastructure for cancer treatment is largely urban and grossly inadequate- India is estimated to have 0.2 comprehensive centres per million versus 4.4 per million as per global standards. We are confident of Cancer Clinics’ model of offering comprehensive cancer care to the patient while eliminating the need to be restricted to any physical location, making it accessible at scale.”

Mayank Parekh, founder & CEO, MVP said, “Healthcare provision will continue to require offline channels. Real growth will therefore require a deeper integration of online and offline formats. This is why for MVP’s first investment in India, we have chosen Cipher Oncology (Cancer Clinics), a startup that has adopted the digital-first, asset light health-care delivery model in the treatment of cancer.”

Cancer Clinics has been founded by Sonali Srungaram and Sasi Sunkara. The duo has started Cancer Clinics on the back of experimentation Sonali did to uncover and address gaps in the health systems addressing the non-communicable disease burden.

Sonali Srungaram added, “Cancer care in emerging economies is ripe for disruption. There is an increasing demand for patient-centric solutions customised for individual needs. With its unique digital, distributed and asset-light model, Cancer Clinics is set to be a part of that solution.”


Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .


  • Follow Us :
  • Tags
  • Axilor Ventures
  • Cancer Clinics
  • Mayank Parekh
  • Natco Pharma

Related News

  • Hyderabad-based Natco Pharma, Hetero Labs, Dr Reddy’s arm bag generic drug contracts in China

    Hyderabad-based Natco Pharma, Hetero Labs, Dr Reddy’s arm bag generic drug contracts in China

  • Hyderabad-based Natco Pharma offers to acquire nearly 36 per cent stake in Adcock Ingram in Rs 2,100-crore deal

    Hyderabad-based Natco Pharma offers to acquire nearly 36 per cent stake in Adcock Ingram in Rs 2,100-crore deal

  • Hyderabad-based Natco Pharma shares crash 19 per cent on poor financial results

    Hyderabad-based Natco Pharma shares crash 19 per cent on poor financial results

  • Hyderabad-based Natco Pharma gets FDA approval for marketing Bosentan Tablets in the United States

    Hyderabad-based Natco Pharma gets FDA approval for marketing Bosentan Tablets in the United States

Latest News

  • Man gets 25-year rigorous imprisonment for sexually assaulting minor in Hyderabad

    7 hours ago
  • Actor Venkatesh unveils TG20 League logo

    7 hours ago
  • Pakistan’s economy suffers amid US-Iran war, says PM Shehbaz

    7 hours ago
  • Head, Klaasen power-hitting propels SRH to 6-wicket win against Mumbai Indians

    7 hours ago
  • Punjab YouTuber accused of spying for Pak ISI granted bail by High Court

    7 hours ago
  • Exit polls deliver mixed verdict in key States

    7 hours ago
  • Bhojshala–Kamal Maula mosque dispute: No clear evidence of Saraswati temple at Bhojshala: MP HC told

    7 hours ago
  • MP: 12 labourers killed, 20 injured in Dhar road mishap

    8 hours ago

company

  • Home
  • About Us
  • Contact Us
  • Privacy Policy

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

  • Telangana Today Telangana Today
Telangana Today Telangana Today

© Copyrights 2024 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam

.